A randomised phase II feasibility study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)
dc.contributor.author | Corrie, P | |
dc.contributor.author | Matin, R | |
dc.contributor.author | Gupta, Avinash | |
dc.contributor.author | Qian, W | |
dc.contributor.author | Wordsworth, S | |
dc.contributor.author | Gibbons, E | |
dc.contributor.author | Chhabra, A | |
dc.contributor.author | Harman, C | |
dc.contributor.author | Mather, C | |
dc.contributor.author | Middleton, M | |
dc.date.accessioned | 2019-04-29T09:49:02Z | |
dc.date.available | 2019-04-29T09:49:02Z | |
dc.date.issued | 2018 | en |
dc.identifier.citation | Corrie PG, Matin RN, Gupta A, Qian W, Wordsworth S, Gibbons E, et al. 1300TiP A randomised phase II feasibility study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM). Ann Oncol. 2018;29(suppl_8):464. | en |
dc.identifier.doi | 10.1093/annonc/mdy289.056 | en |
dc.identifier.uri | http://hdl.handle.net/10541/621808 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1093/annonc/mdy289.056 | en |
dc.title | A randomised phase II feasibility study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM) | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Oncology Centre, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, UK | en |
dc.identifier.journal | Annals of Oncology | en |
dc.description.note | en] | |
refterms.dateFOA | 2020-04-20T11:18:01Z |